Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IRD Opus Genetics	$1.16 +0.9%	$1.08	$0.65 ▼ $1.75	$69.49M	0.01	536,343 shs	72,612 shs
IXHL Incannex Healthcare	$0.73 +24.8%	$0.44	$0.08 ▼ $3.12	$21.84M	7.67	62.38 million shs	379.45 million shs
RPTX Repare Therapeutics	$1.59 -0.3%	$1.50	$0.89 ▼ $4.07	$68.09M	0.93	303,782 shs	108,603 shs
ZIVO ZIVO Bioscience	$18.00 +4.7%	$14.07	$8.85 ▼ $22.15	$68.71M	-0.06	1,084 shs	892 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IRD Opus Genetics	0.00%	-4.17%	-2.54%	+12.75%	+114,999,900.00%
IXHL Incannex Healthcare	0.00%	+54.70%	-44.00%	+170.10%	-66.59%
RPTX Repare Therapeutics	0.00%	+1.27%	+1.92%	+20.45%	-47.18%
ZIVO ZIVO Bioscience	0.00%	-1.37%	+62.90%	0.00%	+118.18%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IRD Opus Genetics	1.6506 of 5 stars	3.5	0.0	1.9	0.0	0.6
IXHL Incannex Healthcare	0.2913 of 5 stars	0.0	2.0	2.5	0.8	0.0
RPTX Repare Therapeutics	2.2146 of 5 stars	3.3	3.0	0.6	2.5	0.6
ZIVO ZIVO Bioscience	0.2706 of 5 stars	0.0	3.0	0.6	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IRD Opus Genetics	3.00	Buy	$7.33	532.18% Upside
IXHL Incannex Healthcare	0.00	N/A	N/A	N/A
RPTX Repare Therapeutics	2.50	Moderate Buy	$4.50	183.91% Upside
ZIVO ZIVO Bioscience	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest IXHL, IRD, ZIVO, and RPTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/27/2025	IRD Opus Genetics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IRD Opus Genetics	$15.42M	4.51	N/A	N/A	$0.21 per share	5.52
IXHL Incannex Healthcare	$10K	2,160.16	N/A	N/A	$0.18 per share	4.08
RPTX Repare Therapeutics	$53.48M	1.27	N/A	N/A	$3.56 per share	0.45
ZIVO ZIVO Bioscience	$15.85K	4,334.76	N/A	N/A	($0.81) per share	-22.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IRD Opus Genetics	-$57.53M	-$1.92	N/A	N/A	N/A	-377.89%	-384.33%	-148.90%	11/11/2025 (Estimated)
IXHL Incannex Healthcare	-$18.46M	-$1.21	N/A	∞	N/A	N/A	-342.92%	-148.64%	9/29/2025 (Estimated)
RPTX Repare Therapeutics	-$84.69M	-$2.58	N/A	N/A	N/A	N/A	-78.25%	-66.85%	11/6/2025 (Estimated)
ZIVO ZIVO Bioscience	-$7.78M	-$2.58	N/A	∞	N/A	N/A	N/A	-2,240.92%	11/12/2025 (Estimated)

Latest IXHL, IRD, ZIVO, and RPTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	IRD Opus Genetics	-$0.25	-$0.12	+$0.13	-$0.12	$4.27 million	$2.88 million
8/8/2025	Q2 2025	RPTX Repare Therapeutics	-$0.56	-$0.39	+$0.17	-$0.39	$2.50 million	$0.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IRD Opus Genetics	N/A	N/A	N/A	N/A	N/A
IXHL Incannex Healthcare	N/A	N/A	N/A	N/A	N/A
RPTX Repare Therapeutics	N/A	N/A	N/A	N/A	N/A
ZIVO ZIVO Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IRD Opus Genetics	0.06	1.90	1.90
IXHL Incannex Healthcare	N/A	2.12	2.12
RPTX Repare Therapeutics	N/A	6.30	6.30
ZIVO ZIVO Bioscience	N/A	0.17	0.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IRD Opus Genetics	14.97%
IXHL Incannex Healthcare	0.43%
RPTX Repare Therapeutics	85.09%
ZIVO ZIVO Bioscience	12.83%

Insider Ownership

Company	Insider Ownership
IRD Opus Genetics	6.60%
IXHL Incannex Healthcare	15.49%
RPTX Repare Therapeutics	11.50%
ZIVO ZIVO Bioscience	48.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IRD Opus Genetics	14	59.91 million	55.95 million	N/A
IXHL Incannex Healthcare	3	29.43 million	24.88 million	Not Optionable
RPTX Repare Therapeutics	180	42.96 million	38.02 million	Optionable
ZIVO ZIVO Bioscience	10	3.82 million	2.91 million	Not Optionable

IXHL, IRD, ZIVO, and RPTX Headlines

Recent News About These Companies

ZIVO Bioscience (NASDAQ:ZIVO) Stock Price Crosses Above 50-Day Moving Average - Should You Sell?

August 22 at 4:30 AM | marketbeat.com

Analyzing ZIVO Bioscience (NASDAQ:ZIVO) & Protalix BioTherapeutics (NYSE:PLX)

August 15, 2025 | americanbankingnews.com

ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in Poultry

June 20, 2025 | businesswire.com

University of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

May 7, 2025 | finance.yahoo.com

University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

May 6, 2025 | businesswire.com

ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry

February 6, 2025 | businesswire.com

Zivo Bioscience issues new shares, raises $1.5 million

January 28, 2025 | msn.com

Tuesday's Insider Activity: Top Buys and Sells in US Stocks Revealed

January 1, 2025 | investing.com

ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza

December 20, 2024 | businesswire.com

ZIVO Stock Earnings: Zivo Bioscience Reported Results for Q4 2023

March 18, 2024 | investorplace.com

Harmony Biosciences Holdings

March 4, 2024 | forbes.com

Regencell Bioscience Holdings Ltd RGC

February 1, 2024 | morningstar.comM

ZIVO Bioscience Announces Uplisting to OTCQB Market

January 29, 2024 | finance.yahoo.com

Ideaya Biosciences

January 18, 2024 | forbes.com

Dare Bioscience Inc DARE

January 14, 2024 | morningstar.comM

Zivo Bioscience Inc (ZIVO) USD0.001

November 11, 2023 | hl.co.uk

Zivo Bioscience (ZIVO) Price Target Increased by 500.00% to 36.72

November 1, 2023 | msn.com

Zivo Bioscience Inc ZIVO

November 1, 2023 | morningstar.comM

ZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens

October 30, 2023 | finance.yahoo.com

Zivo Bioscience Announces 1-for-6 Reverse Stock Split To Regain Compliance

October 26, 2023 | markets.businessinsider.com

Zivo Bioscience to effect reverse stock split to regain compliance with Nasdaq rules

October 26, 2023 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IXHL, IRD, ZIVO, and RPTX Company Descriptions

Opus Genetics NASDAQ:IRD

$1.16 +0.01 (+0.87%)

As of 02:48 PM Eastern

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

Incannex Healthcare NASDAQ:IXHL

$0.73 +0.15 (+24.83%)

As of 02:55 PM Eastern

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

Repare Therapeutics NASDAQ:RPTX

$1.58 -0.01 (-0.31%)

As of 02:55 PM Eastern

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

ZIVO Bioscience NASDAQ:ZIVO

$18.00 +0.80 (+4.65%)

As of 12:22 PM Eastern

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time